Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Glaston wins deal for five new-generation solar lines in China

Glaston Corporation         Press Release                            21 September 2022 at 10.30Glaston Group has signed a contract for five flat tempering lines for solar panel tempering with Chinese Kibing Glass. The order is the first win for Glaston’s new tailor-made concept for the solar industry. In Glaston’s updated strategy, the solar industry is identified as a growth-capturing customer segment. Amid rising concerns over climate change and energy security, significant growth in renewable energy is expected. In China, the solar market is booming and the new installed solar

Zalaris’ Will Jackson has been nominated for the prestigious Luminary Award by CIPP

Zalaris are proud to announce that Will Jackson, Chief Marketing Officer for Zalaris ASA & Managing Director for Zalaris UK & Ireland, has been nominated for the prestigious Luminary Award by the Chartered Institute of Payroll Professionals (CIPP).The CIPP  is the chartered institute for payroll, pensions and reward professionals dedicated to raising the profile of payroll in businesses across the globe.  We are extremely proud that Will has been recognised by such a prestigious industry body for his outstanding representation and contribution to the profession.

Spike Nations returns for third instalment of VALORANT charity tournament

Riot Games teams up with BLAST to deliver the third instalment of the VALORANT tournament Spike Nations next month (14-16 October).12 EMEA-based teams, made up of professional esports players, popular gaming personalities and streamers from the VCT, VRLs, and Game Changers circuits, will represent their region as they compete against each other for a €60,000 prize pool with teams fighting for a bigger share of the winnings to donate to their charity of choice.  Spike Nations was first launched in November 2020 where 10 teams competed, last year it expanded to 12 teams with Eastern Europe

BioStock: Promore Pharma’s leg ulcer treatment to reduce patient suffering

Promore Pharma's candidate ropocamptide is being developed for treatment of venous leg ulcers. This is a patient group that today largely lacks pharmaceutical treatment alternatives and Promore aims to reduce patient suffering as well as reduce the burden wound care places on the carer. For a clearer picture of the problem that Promore Pharma wants to solve, BioStock looks at how venous leg ulcers impact the lives of sufferers.Read the full article about Promore Pharma on www.biostock.se/en/ https://www.biostock.se/en/2022/09/promore-pharma-leg-ulcer-treatment-to-reduce-patient-suffering

Risk Intelligence launches 2025 strategy

Risk Intelligence A/S (“Risk Intelligence” or "Company") hereby publishes its 2025 strategy. A presentation of the strategy is available on the Company's investor website (investor.riskintelligence.eu/strategy).Highlights and goals · Positive net result from 2023 · Average annual revenue growth of 30% with a target 50 MDKK in 2025 · ARR average growth 30% · Market leader in security risk analysis · Refocusing the business on maritime security · Land-based security as an independent business area · Strong commercial partnerships · New ESG objectives  Risk

Transactions in connection with share buy-back programme

On 3 March 2022, H+H International A/S (hereinafter referred to as “H+H” or “the Company”) initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”). The share buy-back programme is expected to be realised over a 12-month period, starting from 4 March 2022. Under the share buy-back programme, H+H may repurchase shares up to a maximum amount of DKK 150 million. Please refer

Vestas to strengthen wind energy supply chain with partnership with LM Wind Power for V172-7.2 MW blades

News release from Vestas Wind Systems A/SAarhus, 21 September 2022 Vestas has signed an agreement with LM Wind Power, a leading manufacturer of wind turbine blades, to develop the wind energy supply chain and scale renewables efficiently for the global energy transition. The agreement includes design and manufacturing of blades for V172-7.2 MW wind turbines of the EnVentus platform. “This new partnership highlights how we are increasingly collaborating with partners in a flexible setup to scale efficiently and build on the foundations we have established across our global supply

New integration sees FleetCheck become part of ABAX’s partner programme

A newly-created integration has seen telematics specialist ABAX integrate with FleetCheck, one of the UK’s leading fleet software and management specialists, and for both companies to announce a new strategic partnership.The application programming interface (API) means that odometer data collected through ABAX products can be accessed directly in FleetCheck’s fleet management software , providing a high level of visibility from a single dashboard. Peter Golding, managing director at FleetCheck, said: “ABAX are one of the

Read original

STACK Infrastructure Connects Data Center to Hafslund Oslo Celsio System for City-Wide Heat Reuse

Project represents the first time heat reuse technology has been retrofitted to a data center in Norway to supply capital city with reutilized, emission-free district heatingOslo, NORWAY — 21 September 2022 — STACK Infrastructure ("STACK"), the digital infrastructure partner to the world’s most innovative companies and leading global developer and operator of data centers, and Hafslund Oslo Celsio (“Celsio”), the district heating provider for Norway’s capital city, have successfully completed a one-year ramp-up and excess heat produced by STACK’s OSL01 data center is now providing heat and

EAB Group Plc commences change negotiations

EAB Group Plc, Stock Exchange Release, 21 September 2022, 10:00 a.m. (EET)   EAB Group Plc commences change negotiations   EAB Group Plc shall today on 21 September 2022 commence change negotiations in accordance with the Co-operation Act, upon request of Evli Plc. The negotiations will involve personnel of EAB Group Plc, which will merge into Evli Plc on or about 1 October 2022, and personnel of EAB Varainhoito Oy, EAB Rahastoyhtiö Oy and Elite Vakuutuspalvelu Oy, which are becoming part of Evli Group on the aforesaid date.   The change negotiations also involve Evli

Hedera Dx raises €14 million in seed funding to accelerate global adoption of liquid biopsies

Liquid biopsy cancer testing is one of the most transformational innovations in healthcare for the next decade, directly unlocking better outcomes for patients.Swiss techbio company  Hedera Dx , founded in 2021 by veteran healthcare entrepreneurs and executives, will be launching this fall a blood-based testing solution to profile cancer DNA circulating in the blood, helping patients access better treatments. To do this, the company has raised €14M in funding.   The round was led by Adam Ghobarah, founder of  

Save the date – Episurf Medical capital markets day 2022

Episurf Medical (Nasdaq: EPIS B) invites investors, analysts, and media to a capital markets day on Wednesday 16 November 2022. Presentations will be held by members of Episurf Medical’s management group, focusing on the company’s global commercial opportunities and strategy for the coming years. “We are clearly entering into a new phase with an increased focus on commercial opportunities. Following several years with a focus on product development and clinical studies, we look forward to providing investors and other interested parties with an update about the next steps”, says Pål

Remedy Entertainment Oyj: Managers' Transactions – Terhi Kauppi

Remedy Entertainment Oyj – Managers' Transactions 21 September 2022 at 9.45 a.m. (EEST)____________________________________________Person subject to the notification requirementName: Terhi KauppiPosition: Chief Financial OfficerIssuer: Remedy Entertainment OyjLEI: 7437003VZ3JPF7DBTG92Notification type: INITIAL NOTIFICATIONReference number: 19748/5/8____________________________________________Transaction date: 2022-09-20Venue not applicableInstrument type: SHAREISIN: FI4000251897Nature of the transaction: SUBSCRIPTION(X) Linked to stock option programme

Remedy Entertainment Oyj: Managers' Transactions – Mikaela Öberg-Mattila

Remedy Entertainment Oyj – Managers' Transactions 21 September 2022 at 9.45 a.m. (EEST)____________________________________________Person subject to the notification requirementName: Mikaela Öberg-MattilaPosition: Other senior managerIssuer: Remedy Entertainment OyjLEI: 7437003VZ3JPF7DBTG92Notification type: INITIAL NOTIFICATIONReference number: 19750/5/4____________________________________________Transaction date: 2022-09-20Venue not applicableInstrument type: SHAREISIN: FI4000251897Nature of the transaction: SUBSCRIPTION(X) Linked to stock option programme

HC Andersen Capital Events 21/09: Meet the top management in NeoDynamics

HC Andersen Capital is hosting a digital event where you can meet and ask questions directly to the top management. It is free for all to attend.NEODYNAMICS – Q&A SESSION WITH CEO ANNA ERIKSRUDIn this Q&A session, we will focus on the FDA’s approval of NeoDynamics innovative pulse biopsy system NeoNavia™.The US market is potentially the largest and is estimated to reach $830 million by 2025.Feel free to ask questions during the presentation.NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing the diagnosis and care of breast cancer. The company’s

Beijer Ref completes new acquisition in South Africa

Beijer Ref has signed an agreement to acquire all assets in Transport Cooling SA, a distributor of transport cooling for trucks and trailers. The company's geographical coverage currently consists of seven branches in South Africa and one branch in Namibia. Annual sales amount to approximately SEK 150 million. Transport Cooling SA is an operating unit of GEA Africa, which is fully owned by GEA Group AG. Over the years, GEA has established good relationships within the transport cooling segment in Southern Africa. Since 1964, Transport Cooling SA has had an exclusive distribution

Mackmyra launches Destination

Mackmyra Destination is a limited single malt whisky aged in port wine casks. The release is based on a recipe that pushes the boundaries of the fuller-bodied spirit aged in American white oak casks, with depth from the port wine casks, while the typical bourbon casks add balance and harmony. A new classic whisky character from the pioneering Swedish distillery. Topped with butterscotch, and lively notes of cherry and blackberry.Mackmyra has various destinations around the globe. Which includes the Whisky Village, the heart and home of the distillery in Gävle, and storage sites around

Episurf Medical provides update on 510(k) application

Episurf Medical (NASDAQ: EPIS B) today announces a status update on the previously communicated 510(k) application to the US FDA for US market clearance for the Episealer® Patellofemoral System. The present submission was filed in April this year and feedback from the substantive review has been received. The company has since been working interactively with the FDA to clarify ambiguities and provide complimentary documentation. There are planned activities to be performed during the autumn to close the remaining questions and take the review process to the final phase. “We are on a good

Q-Free: Traffic Management frame agreement extension in the UK – potential for 88 MNOK sales

Q-Free has received a 3-year frame agreement for delivering traffic counting systems and related services to the Department for Transport in the UK. The customer has options to extend the duration of the contract by 1+1 years. The contract has an expected value of 88 MNOK including options, implying annual sales of ~18 MNOK. In accordance with Q-Free definition of order backlog, frame agreements are not reported as order intake nor included in the order backlog until specific orders under the contract are received. However, this contract is expected to secure a significant volume for our

The Board of Directors resolves on a rights issue of units of approximately SEK 20.1 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. The Board of Directors of Scandinavian ChemoTech AB (publ) ("ChemoTech" or the "Company") has today, with support of the authorisation from the annual general meeting on 24 May 2022, decided to carry out a rights issue of units consisting

Tibnor – an important channel for SSAB’s fossil-free steel in the future

SSAB will start supplying commercial volumes of fossil-free steel to the market in 2026, when also SSAB’s subsidiary Tibnor will be ready to distribute it to customers across the Nordics. ”Tibnor is a very important channel for SSAB on our Nordic home market,” says Matts Nilsson, Head of Sales Sweden & Norway at SSAB Europe. Steel is one of the most important materials in modern society but unfortunately, it is also one of the largest sources of carbon dioxide emissions. SSAB wants to change this, and so is developing a completely fossil-free steel, which the company plans to

Idogen has received approval from the regional ethics committee to conduct a clinical phase I/IIa study within the IDO 8 program for hemophilia at Oslo University Hospital

Idogen AB (publ) announces today that the company has received approval from the Norwegian REK (Regionale komiteer for medicinsk og helsefaglig forskningetikk) in Oslo to conduct the clinical phase I/IIa study of their drug candidate within the IDO 8 program for patients suffering from hemophilia who have developed antibodies against their life-saving factor VIII treatment. The approval means that study activities can begin at the clinic and that the first patient can be enrolled in the study within short.   Idogen has now received approval from the ethics committee in Oslo to conduct

New report - High pressure on the transport industry to shift to electric

Road transport is the most prioritized area to reduce CO2 emissions, according to leading e-commerce and manufacturing companies in Europe. A new report carried out by Ipsos and Volvo Trucks shows that companies are willing to pay more for transport suppliers with lower CO2 emissions. Volvo Trucks believe that electrification will be the key driver towards zero emission road transports. The research company Ipsos has, on behalf of Volvo Trucks, interviewed 100 large e-commerce and manufacturing companies in eight European countries about their demand for fossil fuel free

Tezspire approved in the EU for severe asthma

21 September 2022 07:00 BST Tezspire approved in the EU for the treatment of severe asthma First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations AstraZeneca's Tezspire (tezepelumab) has been approved in the European Union (EU) as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product. The approval by the European Commission was based on results from the PATHFINDER clinical trial programme,

There are no items matching the current filter
There are no more items matching the current filter
Back to top